Novel nonantibiotic therapies for pneumonia: cytokines and host defense.
Effective host defense against bacterial infection is dependent on the activation and recruitment of phagocytic cells. The initiation, maintenance, and resolution of this inflammatory response in the setting of bacterial pneumonia is dependent on the expression of cytokines. As the complexities of the host-pathogen interaction are further dissected and unraveled, immunologic manipulation of cytokine expression will likely become an important adjuvant therapy in the treatment of serious lung infections.
Nelson
S
S
Louisiana State University Health Sciences Center, Department of Medicine, 1901 Perdido St., New Orleans, LA 70112, USA. snelso1@lsuhsc.edu
D000818:Animals; D001691:Biological Therapy; D003428:Cross Infection / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000187:drug effects / Q000502:physiology / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D016753:Interleukin-10 / Q000494:pharmacology / Q000502:physiology; D018664:Interleukin-12 / Q000494:pharmacology / Q000502:physiology; D016209:Interleukin-8 / Q000494:pharmacology / Q000502:physiology; D018410:Pneumonia, Bacterial / Q000276:immunology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000502:physiology
D016207:Cytokines; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D016179:Granulocyte Colony-Stimulating Factor; D018664:Interleukin-12